REG - Oxford Nanopore Tech - London Calling Technology Update

Oxford Nanopore TechnologiesAnnouncement

21/05/2026 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260521:nRSU2494Fa&default-theme=true

RNS Number : 2494F  Oxford Nanopore Technologies plc  21 May 2026

Oxford Nanopore Technologies plc

("Oxford Nanopore" or the "Company")

London Calling Technology Update

Annual customer conference highlights customer-led execution and continued
platform innovation

 

21 May 2026

Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new
generation of nanopore-based sensing technology, presented a Technology Update
at the Company's flagship annual London Calling customer conference.

Opening London Calling 2026, Chief Executive Francis Van Parys highlighted the
Company's continued focus on customer-led platform development, strengthening
the user end‑to‑end experience and supporting broader adoption in applied
and regulated environments. He also underlined ongoing investment in
longer-term innovation to extend platform capabilities.

At the Annual Technology Talk the Company highlighted updates including:

Platform development led by customer need

·      Delivering richer multiomic insight from a single platform:
advances in integrated DNA, RNA and epigenetic data, including methylation,
providing comprehensive insight from a single system.

·     Driving continuous improvement in platform performance, including
accuracy, base modifications, output and speed, with continued enhancement of
unique features such as adaptive sampling. This includes the introduction of
the PromethION Plus Flow Cell, designed to increase output with enhanced yield
achieved without additional wash and reload steps. The Company also
highlighted increasing use of AI-driven methods across basecalling, variant
detection and downstream analysis.

·     Expanding platform capability across core workflows, including
transcriptomics (RNA), microbial and vaccine QC (GridION Q), and high-output
sequencing (PromethION), with new chemistry and workflows shipping from May to
July 2026.

 

Regulatory readiness

·      Advancing reliability and consistency: improvements in
repeatability and robust performance in production environments, enabling
predictable use at scale.

·      Expanding real-world deployment across routine and regulated
settings.

End-to-end experience

·      Simplifying workflows and reducing complexity to support broader
adoption.

·      Advancing integrated software platforms, including EPI2ME, for
accessible and standardised data interpretation.

Longer-term innovation and platform pipeline

·      Continuing investment across chemistry and hardware towards both
low and high output applications, and development of multiomic capability
including protein sequencing, extending the platform into new areas of
biological insight.

·      Showcasing a novel demonstration of peptide sequencing using an
amino-acid calling for accurate protein identification.

A video replay of the Technology Talk is available on the Oxford Nanopore
website here (https://nanoporetech.com/news/london-calling-technology-update)
.

-ENDS-

 

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:     ir@nanoporetech.com (mailto:ir@nanoporetech.com)

Media:           media@nanoporetech.com
(mailto:media@nanoporetech.com)

 

Teneo (communications adviser to the Company)

Tom Murray and Lisa Jarrett-Kerr

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com
(mailto:OxfordNanoporeTechnologies@teneo.com)

 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The company
has developed a new generation of nanopore-based sensing technology for
faster, information rich, accessible and affordable molecular analysis. The
first application is DNA/RNA sequencing, and the technology is in development
for the analysis of other types of molecules including proteins. The
technology is used in more than 125 countries to understand and characterise
the biology of humans and diseases such as cancer, plants, animals, bacteria,
viruses, and whole environments. Oxford Nanopore Technologies products are
intended for molecular biology applications and are not intended for
diagnostic purposes. For more, visit: www.nanoporetech.com
(http://www.nanoporetech.com/)

Forward-looking statements

This announcement contains certain forward-looking statements. For example,
statements regarding expected revenue growth and profit margins are
forward-looking statements. Phrases such as "aim", "plan", "expect", "intend",
"anticipate", "believe", "estimate", "target", and similar expressions of a
future or forward-looking nature should also be considered forward-looking
statements. Forward-looking statements address our expected future business
and financial performance and financial condition, and by definition address
matters that are, to different degrees, uncertain. Our results could be
affected by macroeconomic conditions, delays or challenges in manufacturing or
delivering of products to our customers, suspensions of large projects and/or
acceleration of large products or accelerated adoption of pathogen
surveillance or applied uses of our products. These or other uncertainties may
cause our actual future results to be materially different than those
expressed in our forward-looking statements.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDSEUSIFEMSEII



            Copyright 2019 Regulatory News Service, all rights reserved